Pfizer/BioNTech COVID-19 Vaccine Data For Kids Is Here: What You Need To Know

Pfizer Inc PFE and BioNTech SE BNTX have announced results from one cohort from a Phase 2/3 trial evaluating its COVID-19 vaccine on a two-dose schedule (approximately 21 days apart).
The data from over 2,200 children aged 5 to 11 years showed a favorable safety profile and robust neutralizing antibody responses using a two-dose regimen of 10 µg, a smaller dose than the 30 µg dose used for people 12 and older.
The antibody responses in the participants given 10 µg doses were comparable to those in a prior study in people 16 to 25 immunized with 30 µg doses.
Further, the COVID-19 vaccine was well tolerated, with side effects generally comparable to those observed in participants 16 to 25 years of age.
The companies plan to submit the data to the FDA and other health regulators "as soon as possible."
Topline readouts for the other two age cohorts from the trial – children 2-5 years of age and 6 months to 2 years are expected in Q4 of 2021.
Read Next: FDA Panel Votes Against Approval Of Pfizer/BioNTech's COVID-19 Booster Shot For General Public.
Price Action: PFE stock is down 1.53% at $43.22, while BNTX stock is down 5.27% at $340.24 during the premarket session on the last check Monday.
Photo by x3 from Pixabay